RxDoctor Payments DataLook up a doctor →

Ender Akan, MD

Neurology · Munster, INNPI 1487658282

Payments from drug & device makers

$295,745in general payments, 2019–2025

Across 944 payments — averaging $313.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$207K
  • Amgen$50K
  • Pfizer$21K
  • Axsome Therapeutics, Inc.$9K
  • Biogen$888
  • SK Life Science, Inc.$543
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,5251%
  • Speaking & faculty fees$273,08692%
  • Travel & lodging$5,4982%
  • Food & beverage$15,6345%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)371$207,275
Amgen74$50,087
Pfizer52$21,049
Axsome Therapeutics, Inc.12$9,137
Biogen48$888
SK Life Science, Inc.34$543
Lundbeck LLC25$517
Jazz Pharmaceuticals Inc.18$478
Teva Pharmaceuticals USA, Inc.20$375
Lilly USA, LLC19$349
Novartis21$346
Neurelis, Inc.11$324
UCB, Inc.17$297
Neurocrine Biosciences, Inc.14$288
Acorda Therapeutics, Inc16$235
AstraZeneca(2 entities)11$234
Johnson & Johnson13$227
Avadel CNS Pharmaceuticals, LLC9$223
Acadia Pharmaceuticals Inc12$221
Amneal Pharmaceuticals LLC12$216
Banner Life Sciences, LLC11$208
Supernus Pharmaceuticals, Inc.10$189
Corium, LLC7$155
W. L. Gore & Associates, Inc.1$138
Biohaven Pharmaceutical Holding Company Ltd.12$136
Biohaven Pharmaceuticals, Inc.10$129
Upsher-smith Laboratories LLC8$114
Boston Scientific3$107
MDD US Operations, LLC6$99
EMD Serono, Inc.6$82
Sunovion Pharmaceuticals Inc.4$82
Sanofi4$77
Eisai Inc.4$68
Azurity Pharmaceuticals, Inc.4$67
Impel Pharmaceuticals Inc.4$64
Genentech USA, Inc.3$62
Bristol Myers Squibb3$59
Argenx US, Inc.3$56
TG Therapeutics, Inc.3$55
Arbor Pharmaceuticals, Inc.4$52
Greenwich Biosciences, Inc.1$34
Avanir Pharmaceuticals, Inc.2$33
Promius Pharma LLC2$33
Otsuka America Pharmaceutical, Inc.2$32
Vertical Pharmaceuticals, LLC2$25
Octapharma USA, Inc.1$24
Kyowa Kirin, Inc.1$23
Aucta Pharmaceuticals, Inc.1$22
Tanabe Pharma America, Inc.1$20
Livanova USA, Inc.1$20
Takeda Pharmaceuticals U.S.A., Inc.1$19
Mylan Specialty L.p.1$19
E.r. Squibb & Sons, L.L.C.1$19
Abbott1$18
Mallinckrodt Enterprises LLC1$16
Adamas Pharmaceuticals, Inc.1$16
Scilex Pharmaceuticals Inc.1$16
Currax Pharmaceuticals LLC1$14
Assertio Therapeutics, Inc.1$13
Impel Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$295,745 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$322,599
Medicare patients
760
Services billed
18,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b15$169,854
TecfideraDimethyl Fumarate12$109,005
Aimovig AutoinjectorErenumab-Aooe47$35,052
BotoxOnabotulinumtoxina22$30,692
QuliptaAtogepant23$24,450
NamzaricMemantine Hcl/Donepezil Hcl28$23,427
Nurtec OdtRimegepant Sulfate20$21,867
UbrelvyUbrogepant13$16,203
Memantine Hcl286$9,672
Ajovy AutoinjectorFremanezumab-Vfrm12$8,389
Lacosamide47$7,807
Pregabalin66$3,818
Donepezil Hcl255$2,845
Levetiracetam79$2,349
Gabapentin127$2,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$888$109,00512 claims
AbbVieBotox, Qulipta, Namzaric, Ubrelvy$207,275$94,77286 claims
PfizerNurtec Odt$21,049$21,86720 claims
Upsher-smith Laboratories LLCTopiramate$114$45829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Indiana.

Other neurology in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →